Israel Surrogacy Contracts, Agencies and Payments: Legal Controls and Risks
The practical answer
For a surrogacy arrangement intended to proceed in Israel under the Embryo Carrying Agreements (Agreement Approval and Status of the Newborn) Law, 5756–1996, the key safeguard is not an agency promise or a private signature: the statutory Approval Committee must approve the surrogacy agreement. The arrangement must then be carried out in accordance with the approved text and any conditions attached to the approval.
Payments to the surrogate are not an unrestricted commercial bargain. The Committee may approve monthly payments for actual expenses and reasonable compensation, and the law bars consideration for performing the arrangement outside the approved payments. Agency, clinic and trustee charges should be analysed separately rather than bundled into one unexplained “program price”.
The approval gate is substantive
Sections 5–7 of the Israeli framework make committee approval central: a person must not enter into or perform a surrogacy agreement that has not been approved, or perform it contrary to the approved agreement or approval conditions. The Committee considers the documents and circumstances, including voluntary and informed consent, health-related safeguards and whether the agreement prejudices the rights of the child or any party. The agreement must provide for no more than six embryo-implantation attempts.
Once the amended agreement is approved, the parties sign it before the Committee, which authorizes the process to begin.
The Ministry says the law prevails over conflicting website guidance; verify the current text before acting.
Check eligibility before committing money
Before paying a non-refundable deposit, check that the actual parties meet the current criteria for Israel’s domestic route. The Ministry’s published criteria require intended parents to be Israeli residents. The statutory definition is technical: it refers to an Israeli citizen or permanent resident who has lived in Israel for at least three of the five years, or at least 12 of the 18 months, before the application; confirm the current official text. Each intended parent must be at least 18 and at least one must not yet have turned 54 when the agreement is approved (the Committee may make a special-case exception to the upper age limit). At least one gamete used for IVF must come from an intended parent. The Ministry currently lists a limit of two shared children for a couple or two genetic children for a single intended parent; if a child has died, ask counsel to check whether any later temporary order applies. Certain convictions or pending criminal proceedings can also affect eligibility.
At approval, the surrogate must be an Israeli resident aged 22 to under 39 and must previously have given birth outside surrogacy; children she previously gave birth to must not have been removed from her custody under law. She must have had no more than four prior deliveries. The Ministry’s criteria further require previous deliveries to have been full-term and without complications, with normal birth weight for gestational age and no significant medical complications during pregnancy or childbirth. Other specific medical exclusions and the required interval since the last birth also apply. She must not have been a surrogate more than twice or given birth as a surrogate more than once, and must not fall within the statute’s defined categories of relatives of any intended parent. As a rule, she must be unmarried; the Committee may accept a married surrogate only if its stated conditions are met, including reasonable efforts to find an unmarried surrogate and an opportunity for her spouse to be heard. A religious-affiliation rule also applies: the surrogate must be of the same religion as an intended mother or father, although the Committee may depart from this rule if all parties are non-Jewish. The Ministry also requires medical documents specific to the applicant category; where an intended mother is part of the application, the Ministry calls for a specialist opinion explaining her inability to conceive or carry a pregnancy, or that pregnancy may significantly endanger her health. Check the complete current criteria before signing or paying.
This is a screening summary, not a complete eligibility opinion. The Ministry describes preliminary threshold review as a voluntary step reserved for special cases. An agency pre-screening or threshold review is not final approval of the agreement. Ask independent Israeli counsel to check the facts against the current Hebrew law and Ministry checklist before paying a non-refundable fee.
Check where each part of the process will take place
The Ministry’s summary of the domestic route says that IVF, embryo implantation, pregnancy and birth are to take place in Israel. The Approval Committee may authorize part of the pregnancy to take place abroad only for justified reasons and on conditions it sets. An agency or clinic cannot grant that permission itself. If any treatment or pregnancy stage is proposed outside Israel, obtain a written, transaction-specific Israeli legal assessment and confirm any required Committee authorization before signing or transferring funds. Parentage, citizenship and travel rules in another country remain separate questions.
Use separate documents and independent lawyers
Treat the paperwork as a coordinated set, not as one generic agency contract. The core surrogacy agreement should identify the parties’ roles, approved payment arrangements, insurance, communication and information-sharing rules, expense evidence, key milestones, emergency arrangements and what happens if the process stops.
A separate agency or brokerage agreement should identify the actual service provider, tasks promised, fee calculation, currency and tax treatment, payment dates, when a fee is earned, refunds, subcontractors, conflicts, records and dispute process. A clinic’s medical-services contract should separately state what its quote includes and excludes. Trust and insurance documents must not contradict the approved agreement.
The Ministry instructs that the intended parents and surrogate have different lawyers. The surrogate chooses her own lawyer, who should be experienced in Israeli surrogacy; the intended parents pay that lawyer’s fees and expenses. That payment does not make the lawyer counsel for the intended parents. The agency may help with logistics, but it should not control the surrogate’s choice of lawyer or replace confidential, independent advice.
What may be paid to the surrogate
Section 6 allows the Approval Committee to approve monthly payments to cover actual expenses connected with the arrangement, including legal advice and insurance premiums. It may also approve compensation for time, suffering, loss of income, temporary loss of earning capacity or other reasonable compensation. The approved agreement and Committee decision, not a market quote, determine the permitted payment arrangement.
The law also prohibits a party or prospective party from giving or accepting consideration in money or money’s worth for performing the Israeli arrangement other than payments approved by the Committee. Do not assume that a “thank-you” bonus, gift, cash envelope, payment to a relative, cryptocurrency transfer or amount routed through an agency falls outside the rule merely because it is described differently. Substance and purpose matter.
Do not add compensation through a side letter, a later invoice or a private promise. The official materials do not provide a universal amount or tariff for surrogate compensation; do not import a foreign rate card or an agency’s package price as proof of what the Israeli Committee will approve.
Agency and brokerage fees
The Ministry says the application process is the same whether the case is filed privately or through an agency, and its current filing guidance lists a brokerage agreement among the joint documents where applicable. This means an intermediary’s involvement should be documented; it does not mean the agency replaces the statutory approval process or that every agency charge is automatically approved.
Before signing, ask who the contracting entity is and what the fee actually buys: matching, coordination, translation, document preparation, case management or another service. Require a written breakdown of the fee, taxes, currency, payment milestones, third-party costs, subcontractors, services that are excluded, and what happens if the agency stops working, the match fails, the clinic changes, or the parties terminate the process. Check whether the agency may retain a deposit and on what documented basis.
The reviewed public materials do not establish a universal agency-commission cap. Have independent Israeli counsel check the specific intermediary, agreement and payment route, especially where fees are split, paid in cash or routed abroad.
Clinic costs and the trust account
Obtain an itemised clinic quote and a separate written medical-services contract. Check whether the price includes IVF and implantation cycles, medicines, donor material if relevant, cryostorage, tests, anaesthesia, additional procedures, complications, cancellation and any extra attempt. Identify the legal entity providing treatment and confirm that the IVF is performed in a recognised department under the Israeli framework. A clinic contract cannot authorise an unapproved surrogacy arrangement or amend the Committee-approved payment terms.
The Ministry’s application instructions say that a trustee should be selected for the trust account holding the process consideration, but that the money should not yet be deposited at that preliminary stage. Follow the Committee’s current directions on when the account is funded. Before transferring money, independently verify the trustee’s identity, the account holder, trust deed, who may release funds, the evidence required for release, account fees, reporting, treatment of interest, unused balances and the process for resolving a dispute.
Before transferring funds, independently verify the recipient and retain the signed agreement, invoice, bank confirmation and receipt.
A payment-control matrix
Use this matrix to reconcile the documents before signing.
| Cost item | What the documents should specify | Main control |
|---|---|---|
| Surrogate payments | Approved schedule, payment dates, expense categories and evidence | No private top-ups or in-kind benefits outside approval |
| Surrogate’s lawyer | Separate engagement; surrogate chooses counsel; fees paid by intended parents | Keep client identity and independent advice clear |
| Insurance | Policy, insured persons, exclusions, premiums, term and claims contact | Confirm the cover is effective and accurately underwritten |
| Clinic and medical services | Itemised quote, included cycles, additional procedures and cancellation terms | Separate included services from estimates and extras |
| Agency or broker | Service scope, fee, milestones, termination, refund terms and subcontractors | Do not treat the fee as a surrogate payment or assume it is refundable |
| Trustee | Trust deed, deposit timing, release authority, account fees and unused balance | Verify the account and release conditions before funding |
Amendments, cancellation and refunds
Any change to an approved surrogacy agreement requires Approval Committee approval. Before embryo implantation, changes in information supplied to the Committee must be reported promptly; the Committee may reconsider its approval if material circumstances change before implantation. Do not rely on an email, messaging-app exchange, invoice, agency schedule or side letter to change approved compensation or duties. Have counsel submit the proposed amendment and obtain any required approval before acting on it.
Separately identify what happens after a failed IVF cycle, a decision not to attempt another cycle, pregnancy loss, multiple pregnancy, hospitalisation, a medical contraindication, withdrawal by a party, relationship breakdown, death or incapacity, or non-performance by the agency or clinic. Specify which fees are earned, which costs are reimbursable, what evidence is required, who reconciles the account, how unused money is returned and how a dispute is handled.
The public sources do not establish one universal refund formula for clinic or agency fees. This does not mean a refund is always due or always barred. The outcome depends on the contract, applicable mandatory rules and facts. Ask Israeli counsel to test each termination, refund and liability clause against the approved agreement, Committee conditions, insurance terms and the rights of all parties.
Consent and medical decision-making
The Committee must be satisfied that all parties entered the agreement voluntarily and understood its meaning and consequences, and that the terms do not prejudice the rights of the child or any party. The agreement should therefore explain how medical information is shared, who communicates with the clinic, how counselling and emergencies are handled, and how each party can obtain independent advice.
Do not draft as if the intended parents can command the surrogate’s body or as if the surrogate can guarantee implantation, a particular birth, a test result or a specific medical outcome. Any clause about abortion, fetal reduction, invasive testing, embryo transfer or refusal of treatment needs individual Israeli legal and medical review; the general public guidance does not settle every such question. Keep medical consent distinct from payment mechanics and avoid coercive financial penalties for exercising legal rights or following medical advice.
Section 18 separately preserves the requirement for informed consent to medical treatment and states that neither the statute nor an approved agreement may prevent the surrogate from receiving treatment or undergoing a medical procedure according to her wishes, including pregnancy termination under applicable law. The current consolidated Hebrew text and its interaction with other laws must be confirmed by counsel; do not rely on contract wording to compel treatment or replace consent.
The Ministry publishes forms describing the surrogate’s rights and direct contact with the Committee.
Documents and filing sequence
Build the file against the current Ministry checklist rather than copying another case. The Ministry’s full-file checklist is marked updated 05/2026; use that version instead of an older copied list. The published guidance lists, among other items, the draft surrogacy agreement, application Form 1, the recommended expectations-discussion Form 11, a brokerage agreement if applicable, letters, a mutual-release agreement if relevant, identity and population-register records, affidavits, medical and psychological reports, confidentiality waivers, criminal-record consents or reports, and the surrogate’s insurance quotation. Exact requirements depend on the parties and the current rules.
The current instructions call for four hard copies of the complete file and an emailed scan arranged consecutively into three PDF files, each no larger than 15 MB. Administrative requirements can change, so recheck the current page and Committee instructions immediately before filing.
Maintain version control. Ensure the final signed agreement, payment schedule, brokerage contract, clinic quote, trust deed, insurance terms and Committee conditions align. Keep proof of filing, approval, signatures, deposits, invoices and every payment.
Red flags before money moves
Pause if an agency says Committee approval is only a formality; asks for surrogate compensation in cash outside the approved schedule; proposes an unapproved side letter; refuses to disclose the full fee or refund formula; controls the surrogate’s lawyer; says one lawyer represents both sides; requests payment to a personal account; will not provide the trust deed or release terms; gives the agency unilateral power to change fees; or supplies a clinic quote without exclusions and additional-cost terms.
Also be wary of guarantees of a successful pregnancy, parentage order, passport or visa. Those outcomes depend on medical facts and separate legal processes; a contract or marketing statement cannot guarantee them. These warning signs do not, by themselves, prove illegality or fraud, but they justify a written explanation and independent review.
Before signing or paying, pause, preserve messages and invoices, and obtain written advice from an Israeli lawyer independent of the agency. If approval already exists, do not try to fix a problem through an informal payment or document change.
Example and points to confirm
Example. After Committee approval, an agency sends a separate invoice for an extra “surrogate support bonus” payable directly to the surrogate. Do not pay simply because the invoice is separate from the approved agreement. The statutory treatment depends on the payment’s substance and purpose, not its label or routing. Ask independent Israeli counsel to determine whether the amount is consideration connected with performance of the arrangement, whether Committee approval is required, and how the payment must be disclosed. A genuinely separate agency-service fee also needs its own contractual and filing analysis; a separate invoice alone does not establish that it is lawful or exempt. Conversely, the existence of an agency fee does not by itself establish illegality. Do not pay until the legal classification and any approval requirements are clear.
This guide uses Ministry guidance and indexed legal text; direct access to some official files was blocked. No agency, clinic or live fee was audited. Have independent Israeli counsel confirm current law, forms, provider status and the transaction facts before acting.
Sources and verification limits
The Ministry’s guidance states that the statute prevails if there is a conflict. Verify current Hebrew law and filing instructions before acting.
- S1 — Israel Ministry of Health — Surrogacy in Israel.https://www.gov.il/en/service/embryo-carryingOfficial Ministry guidance. Confirm the full current official guidance.
- S3 — Israel Ministry of Health — Director-General Circular 07/2021, implementation guidelines. https://www.gov.il/BlobFolder/policy/mk07-2021/he/files_circulars_mk_mk07_2021.pdf Official Ministry circular 07/2021; the cited wording comes from an indexed extract; confirm it against the full official circular. Confirm that it remains current.
- S4 — Wikisource — Hebrew text reproduction of the Embryo Carrying Agreements Law, 5756–1996 (non-official copy).https://he.wikisource.org/wiki/%D7%97%D7%95%D7%A7_%D7%94%D7%A1%D7%9B%D7%9E%D7%99%D7%9D_%D7%9C%D7%A0%D7%A9%D7%99%D7%90%D7%AA_%D7%A2%D7%95%D7%91%D7%A8%D7%99%D7%9D_%28%D7%90%D7%99%D7%A9%D7%95%D7%A8_%D7%94%D7%A1%D7%9B%D7%9D_%D7%95%D7%9E%D7%A2%D7%9E%D7%93_%D7%94%D7%99%D7%99%D7%9C%D7%95%D7%93%29Accessible Hebrew text reproduction for the statutory definition of Israeli residence and section 18 on informed medical consent. It is not an official consolidated statute; verify the current text, amendments and any temporary orders in official records.
- S5 — Wikisource — reproduction of the 2025 temporary order on the child-count limit (non-official copy). https://he.wikisource.org/wiki/%D7%A6%D7%95_%D7%94%D7%A1%D7%9B%D7%9E%D7%99%D7%9D_%D7%9C%D7%A0%D7%A9%D7%99%D7%90%D7%AA_%D7%A2%D7%95%D7%91%D7%A8%D7%99%D7%9D_%28%D7%90%D7%99%D7%A9%D7%95%D7%A8_%D7%94%D7%A1%D7%9B%D7%9D_%D7%95%D7%9E%D7%A2%D7%9E%D7%93_%D7%94%D7%99%D7%99%D7%9C%D7%95%D7%93%29_%28%D7%94%D7%92%D7%93%D7%9C%D7%AA_%D7%9E%D7%A1%D7%A4%D7%A8_%D7%94%D7%99%D7%9C%D7%93%D7%99%D7%9D_%D7%94%D7%9E%D7%A8%D7%91%D7%99_%D7%95%D7%9E%D7%A1%D7%99%D7%A8%D7%AA_%D7%9E%D7%99%D7%93%D7%A2%29_%28%D7%94%D7%95%D7%A8%D7%90%D7%AA_%D7%A9%D7%A2%D7%94%29 The text says the order took effect on 11 March 2025 for one year and applied to specified applicants whose child had died. Its apparent expiry is 11 March 2026; confirm the official gazette and any later order before relying on this.
- S2 — Knesset — official law record. https://main.knesset.gov.il/apps/legislation/main/laws/2000458 Official legislative record; follow-up link only; the reference does not by itself verify substantive claims.
